Ovarian cancer drugs entering the medical insurance in 2022 include abecyclis capsule, neratinib maleate tablets, niraparib and so on. Abeceli capsule: it is suitable for HR+, HER2-advanced and already metastasized breast cancer patients, belongs to the first-line treatment of hormonal first-line targeted therapeutic drugs, and the price of medical insurance is 4,584 yuan per box. Neratinib maleate tablets: mostly used for breast cancer patients with epidermal growth factor gene mutation, can effectively prolong the survival cycle of patients, but there will be liver and kidney damage, bone marrow suppression and so on. Niraparib: belongs to the breast cancer PD-1, PARP inhibitor representative drugs, is a first-line new treatment drugs, after the inclusion of medical insurance drugs, the price is reduced to 4584 yuan a box.